• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种通过CD46靶向的新型膀胱癌特异性溶瘤腺病毒及其与顺铂联合对CAR阴性表达癌细胞的作用。

A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.

作者信息

Cao Wenjuan, Tian Junqiang, Li Chong, Gao Yanjun, Liu Xingchen, Lu Jianzhong, Wang Yuhan, Wang Zhiping, Svatek Robert S, Rodriguez Ronald

机构信息

Institute of Urology, The Second Hospital of Lanzhou University, Key Laboratory of Urological Diseases in Gansu Province, Gansu Nephro-Urological Clinical Center, Cui Yingmen 82, Lanzhou, 730030, China.

Department of Urology, University of Texas Health Science Center San Antonio 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA.

出版信息

Virol J. 2017 Aug 8;14(1):149. doi: 10.1186/s12985-017-0818-1.

DOI:10.1186/s12985-017-0818-1
PMID:28789701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5549334/
Abstract

BACKGROUND

Conditionally replicative oncolytic adenoviruses (CRAds) display significant anti-tumor effects. However, the traditional adenovirus of serotype 5 (Ad5) entering cancer cells via coxsackie virus and adenovirus receptor (CAR) can't be utilized for bladder cancer with low expression of CAR, which limits the application of Ad5.

METHODS

We utilized Ad5/F11p containing the chimeric fiber gene encoding the Ad5 fiber tail domain and Ad11p fiber shaft and knob domains to construct bladder cancer-specific chimeric type viruses Ad5/F11p-PSCAE-UPII-E1A, which can infect bladder cancer cells mediated by CD46 molecule. We carried out series of experiments in vitro to research anti-tumor effect of Ad5/F11p-PSCAE-UPII-E1A and the interaction in combination with cisplatin.

RESULTS

The results demonstrated Ad5/F11p-PSCAE-UPII-E1A could infect bladder cancer cells (T24, EJ and 5637) in a CAR-independent way, and exert anti-tumor effect by blocking the cancer cells in G1 phase and inducing apoptosis. Ad5/F11p-PSCAE-UPII-E1A plus cisplatin enhanced the anti-proliferative effect and increased the number of apoptotic cells compared with viruses or cisplatin alone. Ad5/F11p-PSCAE-UPII-E1A plus cisplatin could upregulate the proteins expression of p53, Bax, and cleaved caspase-3, and downregulated Bcl-2 protein expression in T24, EJ and 5637 cells.

CONCLUSION

We constructed a bladder cancer-specific oncolytic adenovirus and provided new combination treatment strategies for bladder cancer.

摘要

背景

条件性复制溶瘤腺病毒（CRAds）具有显著的抗肿瘤作用。然而，传统的5型腺病毒（Ad5）通过柯萨奇病毒和腺病毒受体（CAR）进入癌细胞，对于CAR低表达的膀胱癌无法利用，这限制了Ad5的应用。

方法

我们利用含有编码Ad5纤维尾结构域以及Ad11p纤维杆和纤维结结构域的嵌合纤维基因的Ad5/F11p构建膀胱癌特异性嵌合型病毒Ad5/F11p-PSCAE-UPII-E1A，其可通过CD46分子介导感染膀胱癌细胞。我们在体外进行了一系列实验，研究Ad5/F11p-PSCAE-UPII-E1A的抗肿瘤作用以及与顺铂联合使用时的相互作用。

结果

结果表明，Ad5/F11p-PSCAE-UPII-E1A能够以不依赖CAR的方式感染膀胱癌细胞（T24、EJ和5637），并通过将癌细胞阻滞在G1期和诱导凋亡发挥抗肿瘤作用。与单独使用病毒或顺铂相比，Ad5/F11p-PSCAE-UPII-E1A联合顺铂增强了抗增殖作用并增加了凋亡细胞数量。Ad5/F11p-PSCAE-UPII-E1A联合顺铂可上调T24、EJ和5637细胞中p53、Bax和裂解的caspase-3的蛋白表达，并下调Bcl-2蛋白表达。

结论

我们构建了一种膀胱癌特异性溶瘤腺病毒，并为膀胱癌提供了新的联合治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/65ae6825b1ee/12985_2017_818_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/736e8b80ee60/12985_2017_818_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/79ff9c14ebbd/12985_2017_818_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/68285613e168/12985_2017_818_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/8204fd9bbfef/12985_2017_818_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/bae369b09e6a/12985_2017_818_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/6406d2b5f8fa/12985_2017_818_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/24f11ccd74aa/12985_2017_818_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/bf64b935dec7/12985_2017_818_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/b41d2498c2ec/12985_2017_818_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/65ae6825b1ee/12985_2017_818_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/736e8b80ee60/12985_2017_818_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/79ff9c14ebbd/12985_2017_818_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/68285613e168/12985_2017_818_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/8204fd9bbfef/12985_2017_818_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/bae369b09e6a/12985_2017_818_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/6406d2b5f8fa/12985_2017_818_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/24f11ccd74aa/12985_2017_818_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/bf64b935dec7/12985_2017_818_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/b41d2498c2ec/12985_2017_818_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3fd/5549334/65ae6825b1ee/12985_2017_818_Fig10_HTML.jpg

相似文献

1
A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.一种通过CD46靶向的新型膀胱癌特异性溶瘤腺病毒及其与顺铂联合对CAR阴性表达癌细胞的作用。
Virol J. 2017 Aug 8;14(1):149. doi: 10.1186/s12985-017-0818-1.
2
Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.膀胱癌特异性溶瘤腺病毒基因治疗与顺铂联合用于体外膀胱癌治疗
Tumour Biol. 2014 Nov;35(11):10879-90. doi: 10.1007/s13277-014-2353-7. Epub 2014 Aug 2.
3
Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.携带 E1A-雄激素受体的膀胱癌特异性腺病毒在膀胱癌中的抗肿瘤作用。
Gene Ther. 2012 Nov;19(11):1065-74. doi: 10.1038/gt.2011.180. Epub 2012 Jan 5.
4
Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.放疗与组织特异性重组溶瘤腺病毒联合治疗对膀胱癌细胞的影响。
Int J Radiat Biol. 2017 Feb;93(2):174-183. doi: 10.1080/09553002.2017.1231942. Epub 2016 Oct 14.
5
Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.膀胱癌特异性重组溶瘤腺病毒在裸鼠皮下异种移植肿瘤模型中的分布与安全性评估。
Curr Gene Ther. 2012 Apr 1;12(2):67-76. doi: 10.2174/156652312800099599.
6
A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.一种衣壳修饰的、条件性复制的表达TRAIL的溶瘤腺病毒载体在人胶质母细胞瘤模型中导致增强的癌细胞杀伤作用。
Cancer Res. 2007 Sep 15;67(18):8783-90. doi: 10.1158/0008-5472.CAN-07-0357.
7
Synergistic effect of bladder cancer-specific oncolytic adenovirus in combination with chemotherapy.膀胱癌特异性溶瘤腺病毒与化疗联合的协同作用。
Oncol Lett. 2017 Aug;14(2):2081-2088. doi: 10.3892/ol.2017.6416. Epub 2017 Jun 19.
8
Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell.膀胱上皮特异性重组腺病毒的构建及其对膀胱癌细胞的抑制作用。
Urol Int. 2009;82(2):209-13. doi: 10.1159/000200802. Epub 2009 Mar 19.
9
Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.重新靶向可提高端粒酶依赖性溶瘤腺病毒对头颈部癌的疗效。
Oncol Rep. 2009 Jan;21(1):165-71.
10
Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.利用新型嵌合溶瘤腺病毒进行病毒治疗可延长人胰腺癌细胞异种移植模型的生存期。
Surgery. 2012 Sep;152(3):441-8. doi: 10.1016/j.surg.2012.05.040. Epub 2012 Jul 31.

引用本文的文献

1
Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).溶瘤病毒疗法的耐药性：多维机制与治疗突破（综述）
Int J Mol Med. 2025 Nov;56(5). doi: 10.3892/ijmm.2025.5612. Epub 2025 Aug 24.
2
Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects.用于治疗膀胱癌的溶瘤病毒：进展、挑战与前景
J Clin Med. 2022 Nov 26;11(23):6997. doi: 10.3390/jcm11236997.
3
The Oncolytic Virus 922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.

本文引用的文献

1
Recent advances in oncolytic adenovirus therapies for cancer.溶瘤腺病毒癌症治疗的最新进展。
Curr Opin Virol. 2016 Dec;21:9-15. doi: 10.1016/j.coviro.2016.06.009. Epub 2016 Jul 2.
2
Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines.膀胱癌：美国临床肿瘤学会认可欧洲泌尿外科学会肌层浸润性膀胱癌指南。
Nat Rev Urol. 2016 Aug;13(8):440-1. doi: 10.1038/nrurol.2016.114. Epub 2016 Jul 5.
3
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.膀胱癌发病率和死亡率：全球概述及最新趋势。
溶瘤病毒922 - 947引发间皮瘤中的免疫原性细胞死亡并减少异种移植瘤生长。
Front Oncol. 2019 Jul 12;9:564. doi: 10.3389/fonc.2019.00564. eCollection 2019.
Eur Urol. 2017 Jan;71(1):96-108. doi: 10.1016/j.eururo.2016.06.010. Epub 2016 Jun 28.
4
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.早期尿路上皮癌的综合转录组分析。
Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.
5
Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers.靶向CD46的嵌合型Ad5/35腺病毒基因疗法对结直肠癌的疗效
Oncotarget. 2016 Jun 21;7(25):38210-38223. doi: 10.18632/oncotarget.9427.
6
Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.BCL2、MCM7和CCNE1的表达上调表明在两种人膀胱癌细胞系中存在顺铂耐药性：T24顺铂敏感膀胱癌细胞系和T24R2顺铂耐药膀胱癌细胞系。
Investig Clin Urol. 2016 Jan;57(1):63-72. doi: 10.4111/icu.2016.57.1.63. Epub 2016 Jan 11.
7
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.帕洛诺司琼联合阿瑞匹坦及地塞米松预防尿路上皮癌患者吉西他滨/顺铂化疗引起的恶心和呕吐
Int J Urol. 2015 Oct;22(10):911-4. doi: 10.1111/iju.12842. Epub 2015 Jun 18.
8
Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.膀胱癌特异性溶瘤腺病毒基因治疗与顺铂联合用于体外膀胱癌治疗
Tumour Biol. 2014 Nov;35(11):10879-90. doi: 10.1007/s13277-014-2353-7. Epub 2014 Aug 2.
9
Helper dependent adenovirus vectors: progress and future prospects.辅助依赖性腺病毒载体：进展与未来展望。
Curr Gene Ther. 2013 Oct;13(5):370-81. doi: 10.2174/156652321305131212125338.
10
Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer.靶向整合素的溶瘤腺病毒 AxdAdB3-F/RGD 增强对膀胱癌的抗肿瘤疗效。
Urology. 2014 Feb;83(2):508.e13-9. doi: 10.1016/j.urology.2013.10.025. Epub 2013 Dec 6.